Compare Stocks: GBIO, ADCT, CRBP, and CRBU

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.26 -2.0%	$1.14	$0.78 ▼ $4.98	$162.14M	1.84	1.57 million shs	1.08 million shs
CRBP Corbus Pharmaceuticals	$7.14 -4.2%	$9.42	$6.32 ▼ $20.56	$133.31M	2.63	1.31 million shs	708,199 shs
CRBU Caribou Biosciences	$1.24 -0.8%	$1.52	$1.22 ▼ $3.54	$132.94M	2.28	1.16 million shs	900,966 shs
GBIO Generation Bio	$5.34	$5.48	$3.00 ▼ $6.95	$35.99M	2.05	160,744 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+19.81%	+13.36%	+22.13%	-64.44%
CRBP Corbus Pharmaceuticals	0.00%	-4.86%	-35.85%	-18.31%	-38.02%
CRBU Caribou Biosciences	0.00%	-4.62%	-25.30%	-26.19%	-41.78%
GBIO Generation Bio	0.00%	0.00%	0.00%	0.00%	-7.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.26 -2.0%	$1.14	$0.78 ▼ $4.98	$162.14M	1.84	1.57 million shs	1.08 million shs
CRBP Corbus Pharmaceuticals	$7.14 -4.2%	$9.42	$6.32 ▼ $20.56	$133.31M	2.63	1.31 million shs	708,199 shs
CRBU Caribou Biosciences	$1.24 -0.8%	$1.52	$1.22 ▼ $3.54	$132.94M	2.28	1.16 million shs	900,966 shs
GBIO Generation Bio	$5.34	$5.48	$3.00 ▼ $6.95	$35.99M	2.05	160,744 shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+19.81%	+13.36%	+22.13%	-64.44%
CRBP Corbus Pharmaceuticals	0.00%	-4.86%	-35.85%	-18.31%	-38.02%
CRBU Caribou Biosciences	0.00%	-4.62%	-25.30%	-26.19%	-41.78%
GBIO Generation Bio	0.00%	0.00%	0.00%	0.00%	-7.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	295.57% Upside
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	474.23% Upside
CRBU Caribou Biosciences	2.80	Moderate Buy	$7.75	525.00% Upside
GBIO Generation Bio	2.17	Hold	$8.50	59.18% Upside

Current Analyst Ratings Breakdown

Latest GBIO, ADCT, CRBP, and CRBU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/26/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/14/2026	CRBU Caribou Biosciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$6.00 ➝ $5.00
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
8/7/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$52.00 ➝ $48.00
8/7/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $35.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CRBP Corbus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CRBU Caribou Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$79.58M	2.03	N/A	N/A	($1.50) per share	-0.84
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
CRBU Caribou Biosciences	$10.04M	13.25	N/A	N/A	$1.31 per share	0.95
GBIO Generation Bio	$19.89M	1.81	N/A	N/A	$12.91 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	11/11/2026 (Estimated)
CRBU Caribou Biosciences	-$148.12M	-$1.08	N/A	N/A	N/A	-1,030.42%	-89.11%	-62.47%	11/11/2026 (Estimated)
GBIO Generation Bio	-$131.67M	-$9.34	N/A	N/A	N/A	-410.13%	-94.82%	-34.13%	N/A

Latest GBIO, ADCT, CRBP, and CRBU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	CRBU Caribou Biosciences	-$0.3240	-$0.24	+$0.0840	-$0.24	$2.28 million	$1.50 million
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
CRBU Caribou Biosciences	N/A	6.49	6.49
GBIO Generation Bio	N/A	4.44	4.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CRBP Corbus Pharmaceuticals	64.64%
CRBU Caribou Biosciences	77.51%
GBIO Generation Bio	95.22%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
CRBP Corbus Pharmaceuticals	3.50%
CRBU Caribou Biosciences	8.54%
GBIO Generation Bio	21.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
CRBP Corbus Pharmaceuticals	36	18.67 million	18.02 million	Optionable
CRBU Caribou Biosciences	97	107.21 million	98.05 million	Optionable
GBIO Generation Bio	150	6.74 million	5.32 million	Optionable

GBIO, ADCT, CRBP, and CRBU Headlines

Recent News About These Companies

Generation Bio stock holds steady as investors weigh recent trial and cash runway

September 18, 2026 | ad-hoc-news.deA

Generation Bio (GBIO) Receives a Buy from Wedbush

January 6, 2026 | theglobeandmail.com

Generation Bio (GBIO) price target decreased by 70.88% to 9.01

December 21, 2025 | msn.com

Jefferies downgrades Generation Bio (GBIO)

December 18, 2025 | msn.com

Generation Bio price target lowered to $5.50 from $7 at Wedbush

December 16, 2025 | msn.com

Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

December 15, 2025 | prnewswire.com

GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders

December 15, 2025 | businesswire.com

XOMA Royalty Enters into Agreement to Acquire Generation Bio

December 15, 2025 | globenewswire.com

Here's Why We're A Bit Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

December 2, 2025 | uk.finance.yahoo.com

Generation Bio (GBIO) Price Target Increased by 13.40% to 30.94

November 17, 2025 | msn.com

Generation Bio Co. Reports Strategic Restructuring and Financial Highlights

November 6, 2025 | msn.com

Generation Bio Announces Third Quarter 2025 Financial Results

November 5, 2025 | globenewswire.com

Generation Bio CEO McDonough to step down, Howze named interim CEO

October 22, 2025 | msn.com

Generation Bio announces leadership transition

October 22, 2025 | msn.com

Generation Bio Announces CEO Transition

October 22, 2025 | globenewswire.com

Generation Bio price target raised to $10 from $9 at Canaccord

August 19, 2025 | msn.com

Generation Bio Inc. (GBIO) Stock Price Today - WSJ

August 14, 2025 | wsj.com

Generation Bio soars as it explores strategic alternatives

August 14, 2025 | msn.com

Wedbush Downgrades Generation Bio (GBIO)

August 14, 2025 | msn.com

Generation Bio Stock Surged 31% Pre-Market Today – What’s Going On?

August 14, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, ADCT, CRBP, and CRBU Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.26 -0.03 (-2.02%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$1.26 0.00 (-0.32%)

As of 09/25/2026 07:47 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corbus Pharmaceuticals NASDAQ:CRBP

$7.14 -0.31 (-4.16%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.12 -0.02 (-0.34%)

As of 09/25/2026 07:42 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Caribou Biosciences NASDAQ:CRBU

$1.24 -0.01 (-0.80%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.28 +0.04 (+3.63%)

As of 09/25/2026 07:30 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Generation Bio NASDAQ:GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GBIO, ADCT, CRBP, and CRBU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GBIO, ADCT, CRBP, and CRBU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GBIO, ADCT, CRBP, and CRBU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, ADCT, CRBP, and CRBU Company Descriptions

ADC Therapeutics NYSE:ADCT

Corbus Pharmaceuticals NASDAQ:CRBP

Caribou Biosciences NASDAQ:CRBU

Generation Bio NASDAQ:GBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GBIO, ADCT, CRBP, and CRBU Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GBIO, ADCT, CRBP, and CRBU Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GBIO, ADCT, CRBP, and CRBU Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, ADCT, CRBP, and CRBU Company Descriptions

ADC Therapeutics NYSE:ADCT

Corbus Pharmaceuticals NASDAQ:CRBP

Caribou Biosciences NASDAQ:CRBU

Generation Bio NASDAQ:GBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools